News
LYPHF
0.255
NaN%
--
Weekly Report: what happened at LYPHF last week (0414-0418)?
Weekly Report · 4d ago
Weekly Report: what happened at LYPHF last week (0407-0411)?
Weekly Report · 04/14 11:16
Luye Pharma Launches Rotigotine Patch in UK, Expands CNS Treatment Portfolio
TipRanks · 04/10 10:08
Weekly Report: what happened at LYPHF last week (0331-0404)?
Weekly Report · 04/07 11:15
Luye Pharma’s Antidepressant Ruoxinlin® Gains Approval in Macao
TipRanks · 04/07 11:10
Weekly Report: what happened at LYPHF last week (0324-0328)?
Weekly Report · 03/31 11:27
Luye Pharma’s Rivastigmine Patch Gains Approval in Japan
TipRanks · 03/31 11:13
Luye Pharma Reports Mixed Financial Results for 2024
TipRanks · 03/30 10:37
Weekly Report: what happened at LYPHF last week (0317-0321)?
Weekly Report · 03/24 11:15
Weekly Report: what happened at LYPHF last week (0310-0314)?
Weekly Report · 03/17 11:26
Weekly Report: what happened at LYPHF last week (0303-0307)?
Weekly Report · 03/10 11:27
Weekly Report: what happened at LYPHF last week (0224-0228)?
Weekly Report · 03/03 11:27
Weekly Report: what happened at LYPHF last week (0217-0221)?
Weekly Report · 02/24 11:26
Weekly Report: what happened at LYPHF last week (0210-0214)?
Weekly Report · 02/17 11:24
Weekly Report: what happened at LYPHF last week (0203-0207)?
Weekly Report · 02/10 11:17
Weekly Report: what happened at LYPHF last week (0127-0131)?
Weekly Report · 02/03 11:22
Weekly Report: what happened at LYPHF last week (0120-0124)?
Weekly Report · 01/27 11:25
Weekly Report: what happened at LYPHF last week (0113-0117)?
Weekly Report · 01/20 11:16
Luye Pharma Initiates Phase II Trial for CNS Drug LY03015 in China
TipRanks · 01/15 12:07
Luye Pharma’s New Antipsychotic Drug LY03020 Approved for U.S. Clinical Trials
TipRanks · 01/14 13:07
More
Webull provides a variety of real-time LYPHF stock news. You can receive the latest news about Luye Pharma Grou through multiple platforms. This information may help you make smarter investment decisions.
About LYPHF
Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.